Metformin extended release for the treatment of Type 2 diabetes mellitus

Expert Opinion on Pharmacotherapy

Volumn 7, Issue 6, 2006, Pages 803-809

  Schwartz, Sherwyn L ^a   Wu, Jacqueline F ^b   Berner, Bret ^a  

^a Diabetes and Glandular Disease Clinic   (United States)

^b Pharmacokinetics Depomed Inc   (United States)

Author keywords

Extended release; Metformin; Type 2 diabetes

Indexed keywords

GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; HEMOGLOBIN A1C; METFORMIN; SULFONYLUREA; TRIACYLGLYCEROL;

AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG RELEASE; DRUG SOLUBILITY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOGLYCEMIA; INSULIN SENSITIVITY; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; STEADY STATE;

ANIMALS; DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS, TYPE 2; HUMANS; METFORMIN;

EID: 33645807357     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.7.6.803     Document Type: Article

References (23)

1. WILD S, ROGLIC G, GREEN A, SICREE R, KING H: Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care (2004) 27:1047-1053.
2. AMERICAN DIABETES ASSOCIATION: Economic costs of diabetes in the US in 2002. Diabetes Care (2003) 26:917-932.
3. THE DIABETES CONTROL AND COMPLICATIONS TRIAL RESEARCH GROUP: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. (1993) 329:977-986.
4. UK PROSPECTIVE DIABETES STUDY (UKPDS) GROUP: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet (1998) 352:837-853.
5. UK PROSPECTIVE DIABETES STUDY (UKPDS) GROUP: Tight blood pressure control and risk of microvascular and microvascular complications in Type 2 diabetes: UKPDS 38. Br. Med. J. (1998) 317:703-713.
6. SHICHIRI M, KISHIKAWA H, OHKUBO Y, WAKE N: Long-term results of the Kumamoto Study on optimal diabetes control in Type 2 diabetic patients. Diabetes Care (2000) 23(Suppl. 2):B21-B29.
7. UK PROSPECTIVE DIABETES STUDY (UKPDS) GROUP: Effect of intensive blood-glucose control with metformin on complications in overweight patients with Type 2 diabetes (UKPDS 34). Lancet (1998) 352:854-865.
8. HOWLETT HC, BAILEY CJ: A risk-benefit assessment of metformin in Type 2 diabetes mellitus. Drug Saf. (1999) 20:489-503.
9. DUNN CJ, PETERS DH: Metformin. A review of its pharmacological properties and therapeutic use in non-insulin dependent diabetes mellitus. Drugs (1995) 49:721-749.
10. GARBER AJ, DUNCAN TG, GOODMAN AM, MILLS DJ, ROHLF JL: Efficacy of metformin in Type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am. J. Med. (1997) 103:491-497.
11. GUSLER G, GORSLINE J, LEVY G et al.: Pharmacokinetics of metformin gastric-retentive tablets in healthy volunteers. J. Clin. Pharmacol. (2001) 41:655-661.
12. HOU SY, COWLES VE, BERNER B: Gastric retentive dosage forms: a review. Crit. Rev. Ther. Drug Carrier Syst. (2003) 20:459-497.
13. GUSLER GM, HOU SY, CONNOR AL, WILDING IR, BERNER B: Pharmacoscintigraphic evaluation of metformin ER in healthy volunteers. Proceeding of the American Association of Pharmaceutical Scientists Annual Meeting: Salt Lake City, UT, USA (2003).
14. SCHWARTZ S, FONSECA V, BERNER B, CRAMER M, CHIANG Y-K, LEWIN A: Efficacy, tolerability, and safety of a novel once-daily extended-release metformin in patients with Type 2 diabetes. Diabetes Care (2006) 29(4) (In Press).
15. FUJIOKA K, BRAZG RL, RAZ I et al.: Efficacy, dose-response relationship and safety of once-daily extended-release metformin (Glucophage XR) in Type 2 diabetic patients with inadequate glycaemic control despite prior treatment with diet and exercise: results from two double-blind, placebo-controlled studies. Diabetes Obes. Metab. (2005) 7:28-39.
16. FUJIOKA K, PANS M, JOYAL S: Glycemic control in patients with Type 2 diabetes mellitus switched from twice-daily immediate-release metformin to a once-daily extended-release formulation. Clin. Ther. (2003) 25:515-529.
17. WULFFELE MG, KOOY A, DE ZEEUW D, STEHOUWER CD, GANSEVOORT RT: The effect of metformin on blood pressure, plasma cholesterol and triglycerides in Type 2 diabetes mellitus: a systematic review. J. Intern. Med. (2004) 256:1-14.
18. AMERICAN DIABETES ASSOCIATION: Standards of medical care in diabetes - 2006. Diabetes Care (2006) 29(Suppl. 1):S4-S36.
19. RIDDLE M: Combining sulfonylureas and other oral agents. Am. J. Med. (2000) 108(Suppl. 6a):15S-22S.
20. BELL DS, OVALLE F: How long can insulin therapy be avoided in the patient with Type 2 diabetes mellitus by use of a combination of metformin and a sulfonylurea? Endocr. Pract. (2000) 6:293-295.
21. UK PROSPECTIVE DIABETES STUDY (UKPDS) GROUP: A randomized trial of efficacy of early addition of metformin in sulfonylurea-treated Type 2 diabetes (UKPDS 28). Diabetes Care (1998) 21:87-92.
22. DEFRONZO RA, GOODMAN AM: Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N. Engl. J. Med. (1995) 333:541-549.
23. HERMANN LS, SCHERSTEN B, BITZEN PO, KJELLSTROM T, LINDGARDE F, MELANDER A: Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study. Diabetes Care (1994) 17:1100-1109.